Emerging Company Profile: Belgium’s Promethera presented preclinical data for HepaStem, its liver-derived stem cell candidate for NASH, fibrosis and acute-on-chronic liver disease, at the AASLD meeting. With what appears to be a solid safety profile, the company hopes to move into clinical studies in the near term.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Supplies – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2016.

Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.